How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

ON

STO:Oncopeptides
Get a brief AI stock analysisSaves ~ 15 minutes of your time

ON

Oncopeptides ABSTO Oncopeptides Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XSTO - Nasdaq STOCKHOLM AB

FAIR VALUE

Is ONCO undervalued compared to its fair value?

The fair value of ONCO stock is hidden SEK. Relative to the market price of 2.615 SEK Oncopeptides AB is hidden.

Oncopeptides AB is a pharmaceutical company, which is involved in the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22...[More about valuation]

Oncopeptides AB Fair Value

Available for registered user
UNLOCK
What is fair value?

Market cap:

0.05 $B

Price:

2.615 SEK

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.534

FINANCIALS

Oncopeptides AB financial for reporting period

Income Statement

0.0051 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.066 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.068 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0051 B 100%
0.0048 B 94%
-0.066 B -1295%
-0.068 B -1335%

Balance Sheet

0.2 B
-0.0084 B


Financial Position Analysis

Assets

0.2 B
Current Assets
0.16 B
Total non-current assets
0.035 B

Total current liabilities
0.069 B
Total non-current liabilities
0.14 B

Cash Flow Statement

-0.067 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.067 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Oncopeptides AB fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-274 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-1312 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-90 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Oncopeptides Rating

Is ONCO attractive for investment based on fundamental analysis?

ONCO stock rating is hidden. Oncopeptides AB is a hidden by Eyestock methodology.

Get ONCO Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-628

Gross Margin:

102

CFO / Debt ratio:

hidden

Current ratio:

4.621

Debt / Equity ratio:

1.441

ROE:

-274

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

ONCO.ST analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for ONCO.ST to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

Oncopeptides AB dividends

ONCO.ST dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About ONCO.ST stock

About the company Oncopeptides AB

Market cap $B

0.05

Dividend yield

Shares outstanding

90.3687 B

Oncopeptides AB is a pharmaceutical company, which is involved in the development of targeted therapies for hematological diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2017-02-22. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.

ONCO.ST profile

  • Ticker

    ONCO.ST

  • Country

    Sweden

  • Exchange

    XSTO - Nasdaq STOCKHOLM AB

  • Report currency

    SEK - Swedish krone

  • IPO date

    22 February 2017

  • Sector

    Healthсare

  • Industry

    Biotechnology

  • Employees

    40

  • City

    Stockholm

  • Address

    Luntmakargatan 46, 7th floor

  • Cusip

    W6709H108

Frequently Asked Questions

What sector does Oncopeptides operate in?

Oncopeptides operates in Healthсare sector

What is market cap of Oncopeptides?

Market cap of Oncopeptides is 0.05 USD as of 24 Jul 2024

What is market price of one ONCO stock?

Market price of one ONCO stock is 2.615 SEK as of 24 Jul 2024

What is Oncopeptides revenue?

According to the recent report Oncopeptides revenue is 5.072

What is Oncopeptides net income?

According to the recent report Oncopeptides net icnome is -67.705

What is Oncopeptides net income growh rate?

Net income growth rate of Oncopeptides is 32